The present invention relates to the technical field of drug synthesis, and provides a preparation method for an ABT-737 key intermediate and a preparation method for ABT-737. A compound having a structure as represented by formula I is a starting material. First, a carboxyl group in the ...
REACTOME_LAGGING_STRAND_SYNTHESIS REACTOME_SYNTHESIS_OF_PC WAMUNYOKOLI_OVARIAN_CANCER_GRADES_1_2_DN LINDGREN_BLADDER_CANCER_CLUSTER_3_UP REACTOME_EXTENSION_OF_TELOMERES LINDGREN_BLADDER_CANCER_CLUSTER_1_DN AUNG_GASTRIC_CANCER CASORELLI_APL_SECONDARY_VS_DE_NOVO_UP KEGG_BASE_EXCISION_REPAIR PID_WNT_...
To directly assess the effects of Noxa on MCL-1 stability, we monitored the decay of MCL-1 after inhibition of new protein synthesis by cycloheximide treatment. MCL-1 was degraded faster in the presence of Noxa-wt expression than in the absence of Noxa (half-lives, ∼0.5 and ∼1.5 ...
Investigations of the underlying mechanism revealed that this resistance occurred upstream of mitochondrial perturbation and involved de novo synthesis of the antiapoptotic proteins BCL-X(L) and BCL2A1, which were responsible for resistance to low and high ABT-737 concentrations, respectively. Our data...
Even without protein synthesis, ABT-737 treatment reduced association of Bim with Bcl-2 and enhanced binding to Mcl-1 (supplemental Figure 2C). However, this does not exclude the possibility that newly synthesized Bim and Mcl-1 interact preferentially when Bcl-2 is occupied by ABT-737. ...